abstract |
(I) at least one inhibitor of PI3 kinase (PI3K) -delta (e.g., TGR-1202); or a pharmaceutically acceptable salt thereof; (ii) at least one anti-CD20 antibody (e.g., ubylituximab); (Iii) at least one anti-PD-1 antibody (e. G., Pembrolizumab) or an anti-PD-L1 antibody A method and a kit are provided. |